Evidence Table K2. CONTINUOUS outcomes for class RETINOID (ORAL).

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	K.02.01			**Isotretinoin**		**Placebo**		
269 ↑ N=33 Parallel Sev		**Cysts change (%)**	Short (4)	Percent change: -17		Percent change: 33		**0.001**
	K.02.02			**Isotretinoin**		**Dapsone**		
276 N=40 Parallel Sev		**Chest/back total lesions (count)** Baseline counts: 38 (Target) / 39 (Comparator)	Short (4)	Percent Change*: -53	*NS*	Percent Change*: -33	*NS*	**NS***
		Face/neck total lesions (count) Baseline counts: 25 (Target) / 21 (Comparator)	Short (4)	Percent Change*: -64		Percent Change*: -38		**NS***
		Overall change/patient vas (p-value)	Short (4)	Measure: 0	*.01*	Measure: 1	*NS*	
		Total severity/photo (leeds)	Short (4)	Measure: 5 (3.6)	*NS*	Measure: 5 (2.4)	*NS*	**NS***
		Chest/back total lesions (count) Baseline counts: 38 (Target) / 39 (Comparator)	Mid (8)	Percent Change*: -66	*NS*	Percent Change*: -36	*NS*	**NS***
		Face/neck total lesions (count) Baseline counts: 25 (Target) / 21 (Comparator)	Mid (8)	Percent Change*: -76		Percent Change*: -43		**NS***
		Overall change/patient vas (p value)	Mid (8)	Measure: 0	*.001*	Measure: 0	*.05*	
		Total severity/photo (leeds)	Mid (8)	Measure: 5 (3.6)	*.01*	Measure: 6 (4.)	*NS*	**NS***
		Chest/back total lesions (count) Baseline counts: 38 (Target) / 39 (Comparator)	Long (16	Percent Change*: -89	*.01*	Percent Change*: -36	*NS*	**NS***
		Face/neck total lesions (count) Baseline counts: 25 (Target) / 21 (Comparator)	Long (16	Percent Change*: -88	*.0001*	Percent Change*: -57	*.05*	
		Overall change/patient vas (p value)	Long (16	Measure: 0	*.001*	Measure: 0	*.01*	
		Total severity/photo (leeds)	Long (16	Measure: 5 (4.)	*.01*	Measure: 6 (3.6)	*NS*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
276 N=40 Parallel Sev		**Post-therapy chest/back total lesions (count)** Baseline counts: 38 (Target) / 39 (Comparator)	Long (36	Percent Change*: -89	*.01*	Percent Change*: -33	*NS*	**NS***
		Post-therapy face/neck total lesions (count) Baseline counts: 25 (Target) / 21 (Comparator)	Long (36	Percent Change*: -92	*.0001*	Percent Change*: -57		**0.01**
		Post-therapy overall change/patient vas (p value	Long (36	Measure: 0	*.001*	Measure: 1	*NS*	
		Post-therapy total severity/photo (leeds)	Long (36	Measure: 3 (3.6)	*.0005*	Measure: 7 (3.)	*.01*	**NS***
	K.02.03			**Isotretinoin**		**Tetracycline hydrochloride**		
206 ↓ N=30 Parallel Sev		**Comedones+pustules (count)** Baseline counts: 27 (Target) / 18 (Comparator)	Short (4)	Percent Change*: -40		Percent Change*: -49		**NS***
		Cysts (count) Baseline counts: 21 (Target) / 23 (Comparator)	Short (4)	Percent Change*: -25		Percent Change*: -29		**NS***
		Cysts diameters (mm)	Short (4)	Measure: 140 (100.)		Measure: 135 (80.)		**NS***
		Comedones+pustules (count) Baseline counts: 27 (Target) / 18 (Comparator)	Mid (12)	Percent Change*: -66		Percent Change*: -38		**NS***
		Cysts (count) Baseline counts: 21 (Target) / 23 (Comparator)	Mid (12)	Percent Change*: -53		Percent Change*: -47		**NS***
		Cysts diameters (mm)	Mid (12)	Measure: 90 (70.)		Measure: 100 (100.)		**NS***
		Post-therapy long term cyst (count) Baseline counts: 21 (Target) / 23 (Comparator)	Long (34.	Percent Change*: -85		Percent Change*: -73		**0.02**
		Post-therapy comedones+pustules (count) Baseline counts: 27 (Target) / 18 (Comparator)	Long (35	Percent Change*: -94		Percent Change*: -60		**0.01**
		Post-therapy cyst diameters (mm)	Long (35	Measure: 31 (57.6)		Measure: 57 (66.5)		**0.01**
	K.02.05			**Isotretinoin**		**Etretinate**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method		Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
130 Parallel	N=56 Sev		**Nodulocystic change (%)** Count location: Face unspecified.	Short (4)	Percent change: -20		Percent change: -5		
			Nodulocystic change/face (%)	Short (4)	Percent change: -39		Percent change: -19		
			Nodulocystic change (%)	Mid (8)	Percent change: -43		Percent change: -8		**0.05**
			Nodulocystic change/face (%)	Mid (8)	Percent change: -68		Percent change: -20		**0.05**
			Nodulocystic change post-therapy (%)	Long (16	Percent change: -69		Percent change: -33		**0.05**
			Nodulocystic change post-treatment/face (%)	Long (16	Percent change: -72		Percent change: -29		**0.05**
		K.02.06			**Isotretinoin (0.1)**		**Isotretinoin (1.0)**		
190 Parallel	N=48 Mild/mod/sev		**Severity/face (king)** Count location: Face unspecified.	Short (4)	Measure: 2		Measure: 2 (1.5)		**NS**
106 Parallel	N=16 Sev		**Cystic change (%)** Count location: Designated area of face, chest and/or back.	Short (6)	Percent change: -16		Percent change: -44		**NS**
			Cystic diameter change (%)	Short (6)	Percent change: -20		Percent change: -63		**NS**
			Cheilitis duration (%)	Mid (12)	Percent change: 11		Percent change: 12		
			Cystic change (%) Count location: Designated area of face, chest and/or back.	Mid (12)	Percent change: -49		Percent change: -65		**NS**
			Cystic diameter change (%)	Mid (12)	Percent change: -57		Percent change: -76		**NS**
			Desquamation duration (week)	Mid (12)	Measure: 7		Measure: 12		
			Puritus duration (weeks)	Mid (12)	Measure: 5		Measure: 8		
190 Parallel	N=48 Mild/mod/sev		**Severity/face (king)** Count location: Face unspecified.	Mid (12)	Measure: 1 (0.4)		Measure: 1		**NS**
			Severity/face (king)	Long (16	Measure: 0 (0.7)		Measure: 1		**NS**
106 Parallel	N=16 Sev		**Cystic change post-treatment (%)** Count location: Designated area of face, chest and/or back.	Long (20	Percent change: -56		Percent change: -88		**NS**
			Cystic diameter change post-treatment	Long (20	Measure: -67		Measure: -91		**NS**
		K.02.06			**Isotretinoin (0.5)**		**Isotretinoin (0.1)**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Short (4)	Percent change: -15		Percent change: -28		**NS**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Short (4)	Percent change: -20		Percent change: -30		**0.01**
185 ↑ Parallel	N=76 Mod	**Non-inflammatory change (%)**	Short (4)	Percent change: -39		Percent change: -22 (72.4)		
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Mid (12)	Percent change: -67		Percent change: -72		**0.01**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified. Between P-value: .05 > 1.0.	Mid (12)	Percent change: -48		Percent change: -52		**0.05**
185 ↑ Parallel	N=76 Mod	**Non-inflammatory change (%)**	Mid (12)	Percent change: -73 (47.7)		Percent change: -66		
		Non-inflammatory change (%)	Long (16	Percent change: -83 (34.1)		Percent change: -80		
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Long (20	Percent change: -77		Percent change: -77		**0.01**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Long (20	Percent change: -68		Percent change: -58		**0.01**
		Inflammatory change post therapy/face (%) Count location: Face unspecified.	Long (32	Percent change: -90		Percent change: -90		**0.01**
		Inflammatory change/trunk post-therapy (%) Count location: Back or chest unspecified.	Long (32	Percent change: -80		Percent change: -88		**0.01**
185 ↑ Parallel	N=76 Mod	**Post-therapy non-inflammatory change (%)**	Long (32	Percent change: -91		Percent change: -89 (20.1)		
	K.02.06			**Isotretinoin (0.5)**		**Isotretinoin (1.0)**		
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Short (4)	Percent change: -15		Percent change: -32		**NS**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Short (4)	Percent change: -20		Percent change: -5		**0.01**
		Inflammatory change/face (%) Count location: Face unspecified.	Mid (12)	Percent change: -67		Percent change: -70		**0.01**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method		Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
320 Parallel	N=150 Sev		**Inflammatory change/trunk (%)** Count location: Back or chest unspecified. Between P-value: .05 > 1.0.	Mid (12)	Percent change: -48		Percent change: -24		**0.05**
			Inflammatory change/face (%) Count location: Face unspecified.	Long (20	Percent change: -77		Percent change: -90		**0.01**
			Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Long (20	Percent change: -68		Percent change: -56		**0.01**
			Inflammatory change post therapy/face (%) Count location: Face unspecified.	Long (32	Percent change: -90		Percent change: -95		**0.01**
			Inflammatory change/trunk post-therapy (%) Count location: Back or chest unspecified.	Long (32	Percent change: -80		Percent change: -78		**0.01**
		K.02.06			**Isotretinoin (1.0)**		**Isotretinoin (0.1)**		
320 Parallel	N=150 Sev		**Inflammatory change/face (%)** Count location: Face unspecified.	Short (4)	Percent change: -32		Percent change: -28		**0.01**
			Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Short (4)	Percent change: -5		Percent change: -30		**NS**
185 ↑ Parallel	N=76 Mod		**Non-inflammatory change (%)**	Short (4)	Percent change: -48 (38.7)		Percent change: -22 (72.4)		
320 Parallel	N=150 Sev		**Inflammatory change/face (%)** Count location: Face unspecified.	Mid (12)	Percent change: -70		Percent change: -72		**0.01**
			Inflammatory change/trunk (%) Count location: Back or chest unspecified. Between P-value: 1.0 < 0.5.	Mid (12)	Percent change: -24		Percent change: -52		**NS**
185 ↑ Parallel	N=76 Mod		**Non-inflammatory change (%)**	Mid (12)	Percent change: -81 (35.)		Percent change: -66		
			Non-inflammatory change (%)	Long (16	Percent change: -88 (15.4)		Percent change: -80		
320 Parallel	N=150 Sev		**Inflammatory change/face (%)** Count location: Face unspecified.	Long (20	Percent change: -90		Percent change: -77		**0.01**
			Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Long (20	Percent change: -56		Percent change: -58		**0.01**
			Inflammatory change post therapy/face (%) Count location: Face unspecified.	Long (32	Percent change: -95		Percent change: -90		**0.01**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
320 Parallel	N=150 Sev	**Inflammatory change/trunk post-therapy (%)** Count location: Back or chest unspecified.	Long (32	Percent change: -78		Percent change: -88		**0.01**
185 ↑ Parallel	N=76 Mod	**Post-therapy non-inflammatory change (%)**	Long (32	Percent change: -94 (14.7)		Percent change: -89 (20.1)		
	K.02.06			**Isotretinoin (1.0)**		**Isotretinoin (0.5)**		
332 Parallel	N=58 Mild/mod/sev	**Comedones (median)** Count location: Unspecified.	Short (4)	Measure: 100		Measure: 120		
		Infiltrates (median)	Short (4)	Measure: 7		Measure: 5		
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Short (4)	Percent change: -32		Percent change: -15		**0.01**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Short (4)	Percent change: -5		Percent change: -20		**NS**
185 ↑ Parallel	N=76 Mod	**Non-inflammatory change (%)**	Short (4)	Percent change: -48 (38.7)		Percent change: -39		
332 Parallel	N=58 Mild/mod/sev	**Papules (median)** Count location: Unspecified.	Short (4)	Measure: 30		Measure: 36		
		Pustules (median)	Short (4)	Measure: 8		Measure: 10		**NS**
		Comedones (median)	Mid (12)	Measure: 82		Measure: 47		**NS**
		Infiltrates (median)	Mid (12)	Measure: 7		Measure: 5		**NS**
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Mid (12)	Percent change: -70		Percent change: -67		**0.01**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified. Between P-value: 1.0 < 0.5.	Mid (12)	Percent change: -24		Percent change: -48		**NS**
185 ↑ Parallel	N=76 Mod	**Non-inflammatory change (%)**	Mid (12)	Percent change: -81 (35.)		Percent change: -73 (47.7)		
332 Parallel	N=58 Mild/mod/sev	**Papules (median)** Count location: Unspecified.	Mid (12)	Measure: 22		Measure: 18		**"Significant"**
		Pustules (median)	Mid (12)	Measure: 6		Measure: 4		**NS**
		Side effects (number)	Mid (12)	Measure: 6		Measure: 5		**0.002**
185 ↑ Parallel	N=76 Mod	**Non-inflammatory change (%)**	Long (16	Percent change: -88 (15.4)		Percent change: -83 (34.1)		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
320 Parallel	N=150 Sev	**Inflammatory change/face (%)** Count location: Face unspecified.	Long (20	Percent change: -90		Percent change: -77		**0.01**
		Inflammatory change/trunk (%) Count location: Back or chest unspecified.	Long (20	Percent change: -56		Percent change: -68		**0.01**
		Inflammatory change post therapy/face (%) Count location: Face unspecified.	Long (32	Percent change: -95		Percent change: -90		**0.01**
		Inflammatory change/trunk post-therapy (%) Count location: Back or chest unspecified.	Long (32	Percent change: -78		Percent change: -80		**0.01**
185 ↑ Parallel	N=76 Mod	**Post-therapy non-inflammatory change (%)**	Long (32	Percent change: -94 (14.7)		Percent change: -91		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.